Group 1 - As of August 11, 2025, the stock price of Baihe Co., Ltd. is 43.42 yuan, with a decrease of 0.06 yuan, representing a decline of 0.14% from the previous trading day [1] - The trading volume on the same day was 10,426 hands, with a transaction amount of 0.45 billion yuan [1] - In the first quarter of 2025, the company achieved operating revenue of 207 million yuan and a net profit attributable to shareholders of 35.21 million yuan [1] Group 2 - A total of 28.14 million restricted shares will be released for circulation on August 15, 2025, accounting for 43.96% of the company's total share capital [1] - The release involves two shareholders, including the controlling shareholder and actual controller Liu Xinli and supervisor Liu Zhaomin [1] Group 3 - On August 11, 2025, the net outflow of main funds was 4.95 million yuan, with a cumulative net outflow of 15.19 million yuan over the past five trading days [1]

本次上市流通的限售股为公司首次公开发行限售股，共计 28,135,545 股，占 公司总股本的 43.96%，共涉及 2 名股东，限售股锁定期为自公司股票上市之日 起 36 个月，由于公司股票上市后六个月内，连续二十个交易日的收盘价均低于 发行价，锁定期限自动延长六个月，该部分限售股将于 2025 年 8 月 15 日上市流 通。 二、本次限售股形成至今公司股本数量变化情况 广发证券股份有限公司 关于威海百合生物技术股份有限公司首次公开发行部分限售股 上市流通的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为威海 百合生物技术股份有限公司（以下简称"百合股份"或"公司"）首次公开发行 股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督 导》等相关法律法规的要求，对百合股份首次公开发行部分限售股上市流通的事 项进行了核查，核查情况如下： 一、本次限售股上市类型 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准威海百 合生物技术股份有限公司首次公开发行股票的批复》（证监许可〔2022 ...

证券日报网讯8月11日晚间，百合股份（603102）发布关于首次公开发行部分限售股上市流通的公告 称，公司本次股票上市类型为首发股份；股票认购方式为网下，本次股票上市流通总数为28，135，545 股。本次股票上市流通日期为2025年8月15日。 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-030 威海百合生物技术股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 本次股票上市流通总数为28,135,545股。 ? 本次股票上市流通日期为2025 年 8 月 15 日。 一、本次限售股上市类型 威海百合生物技术股份有限公司（以下简称"公司"）经中国证券监督管理 委员会（以下简称"中国证监会"）《关于核准威海百合生物技术股份有限公司 首次公开发行股票的批复》（证监许可〔2022〕36 号）核准，向社会公开发行人 民币普通股（A 股）16,000,000 股，并于 2022 年 1 月 25 日在上海证券交易所主板 上市。 公司首次公 开发行前总股本为 48,000,000 股，首次公 开发行后总股本为 股，占公司总股本的 43.96%，共涉及 2 名股东，限售股锁定期为自公司股票上市 之日起 36 个月，由于公 ...

证券代码：603102 证券简称：百合股份 公告编号：2025-030 威海百合生物技术股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 28,135,545股。 本次股票上市流通总数为28,135,545股。 本次股票上市流通日期为2025 年 8 月 15 日。 三、本次限售股上市流通的有关承诺 根据公司《首次公开发行股票招股说明书》，本次限售股上市流通的有关股 东承诺情况如下： （一）公司控股股东及实际控制人刘新力承诺 自公司首次公开发行股票上市之日起 36 个月内，不转让或者委托他人管理 本人直接或间接持有的公司本次发行前已发行的股份，也不由公司回购本人直接 或间接持有的公司本次发行前已发行的股份。 本人在公司担任董事、监事或高级管理人员期间，每年转让的股份不超过本 人直接或间接持有公司股份总数的 25%，本人离职后六个月内，不转让本人直接 或者间接持有的公司股份。 一、本次限售 ...

广发证券股份有限公司 关于威海百合生物技术股份有限公司首次公开发行部分限售股 上市流通的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐机构"）作为威海 百合生物技术股份有限公司（以下简称"百合股份"或"公司"）首次公开发行 股票并上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号—持续督 导》等相关法律法规的要求，对百合股份首次公开发行部分限售股上市流通的事 项进行了核查，核查情况如下： 一、本次限售股上市类型 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准威海百 合生物技术股份有限公司首次公开发行股票的批复》（证监许可〔2022〕36 号） 核准，百合股份首次向社会公开发行人民币普通股（A 股）股票 1,600 万股，并 于 2022 年 1 月 25 日在上海证券交易所主板上市。公司首次公开发行股票前总股 本为 4,800 万股；首次公开发行股票后总股本为 6,400 万股，其中包括有限售条 件流通股 4,800 万股，无限售条件流通股 1,600 万股。 本次上市流通的限售股为公司首次公开发行限 ...

Group 1 - The core viewpoint of the article highlights the growth in the number of manufacturing enterprises in China, with a total of 2,332 companies reported in the first half of 2025, marking an increase of 126 companies or a year-on-year growth of 5.71% [1] - The proportion of these manufacturing enterprises accounts for 0.45% of the total industrial enterprises [1] - The data referenced pertains to large-scale industrial enterprises, with the threshold for classification raised from an annual main business income of 5 million to 20 million yuan since 2011 [1] Group 2 - The article mentions several listed companies in the textile and food sectors, including Huafang Co., Ltd. (600448), Fengzhu Textile (600493), Jiangnan High Fiber (600527), and others [1] - The report referenced is titled "Analysis of the Competitive Landscape and Investment Development Research Report of China's Manufacturing Industry from 2025 to 2031" published by Zhiyan Consulting [1][2] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, specializing in in-depth industry research and providing comprehensive consulting services for investment decisions [2]

Core Viewpoint - The article highlights the active cash dividend distribution by listed companies in the 2024 fiscal year, with a total of 3,679 companies proposing distribution plans, reflecting a strong emphasis on cash dividends encouraged by regulatory bodies [1] Summary by Relevant Sections Dividend Distribution Overview - A total of 3,679 companies have proposed distribution plans for the 2024 fiscal year, with 3,674 of these including cash dividends, amounting to a total cash payout of 1.64 trillion yuan [1] - There are 347 companies that have included stock transfers in their distribution plans for 2024 [1] Important Dates for Investors - Investors should pay attention to two key dates during the dividend distribution season: the ex-dividend date and the record date [1] - As of now, 3,548 companies have implemented their distribution plans, and the focus will be on whether these companies can achieve a "filling rights" market trend [1] Companies with Upcoming Dividend Payments - Six companies have their record date today, with four of them offering cash dividends of 1 yuan (after tax) or more per 10 shares [1] - The company with the highest cash payout is Baihe Co., Ltd., offering 7.50 yuan per 10 shares, followed by Yinlefen and Shandong Expressway, with payouts of 5.00 yuan and 4.20 yuan respectively [1] Upcoming Dividend Payment Details | Stock Code | Stock Name | Cash Dividend per 10 Shares (yuan) | Stock Transfer per 10 Shares | Latest Closing Price (yuan) | 5-Day Price Change (%) | | --- | --- | --- | --- | --- | --- | | 002832 | Yinlefen | 5.000 | - | 16.30 | -1.63 | | 600350 | Shandong Expressway | 4.200 | - | 10.08 | -2.04 | | 300457 | Yinghe Technology | 1.170 | - | 20.46 | -2.48 | | 603102 | Baihe Co., Ltd. | 7.500 | - | 42.85 | -3.73 | | 601456 | Guolian Minsheng | 0.560 | - | 11.12 | -3.89 | | 600638 | Xinhuangpu | 0.370 | - | 5.87 | -4.08 | [1]

转自：大众报业·齐鲁壹点 齐鲁晚报·齐鲁壹点 魏银科 张志恒 一纸评审表，掀起无数波澜。近日，记者获悉，在多家媒体报道百合股份（603102.SH）"回扣门"事件 后，爆料方海莱云视及相关媒体收到了百合股份发出的律师函，被指责"恶意截取未审批通过的内部文 件，擅自披露未审结诉讼证据"。 为回应外界关切，海莱云视于7月25日下午在济南市鑫盛大厦召开媒体说明会，首次将一份百合股份向 其发送的官方书面说明函公之于众，并就《合同评审表》的真实性与合法性等关键问题进行了详细说 明。 海莱云视在说明会上直指争议核心：涉事《合同评审表》是否真实？海莱云视强调，该表是在案件审理 期间，由公司代理律师通过法院阅卷，从百合股份向法院提交的资料中获取。同时，百合股份此前发给 海莱云视的说明函也已明确，该合同评审表确系其提交。 针对百合股份律师函中提及的多项质疑，海莱云视逐一进行回应。首先，关于证据获取的合法性，海莱 云视指出，相关证据材料来自一审公开审理阶段。由于一审为公开审理，且案件不属于保密范畴，依据 法律规定，审理结束后可依法进行阅卷，所以获取证据的过程完全符合法律规定。 其次，在合同评审表的有效性方面，海莱云视强调，该表涵 ...

Core Viewpoint - The controversy surrounding Baihe Co., Ltd. (603102.SH) has intensified following the "kickback" incident, with both Baihe and the whistleblower, Hailai Yunshi, presenting conflicting claims regarding the authenticity and legality of a contract review form [1][6]. Group 1: Contract Review Form Authenticity - Hailai Yunshi asserts that the disputed contract review form was obtained legally during the public trial phase of a case, as it was part of the documents submitted by Baihe to the court [3][4]. - The company emphasizes that the contract review form contains essential information such as incentive targets, incentive policies, contract risks, and product gross margins, and indicates that it has been approved by various management levels [4]. Group 2: Legal and Financial Implications - Hailai Yunshi argues that the process of obtaining evidence is compliant with legal standards, as the trial was public and the case is not confidential, allowing for document review post-trial [4]. - Baihe Co. has consistently denied any payments of kickbacks or fees to Liu Yongtao or related parties, asserting that the contract review form does not include any kickback content and that any related statements were merely personal proposals from business personnel [5][6]. Group 3: Ongoing Developments - As of July 28, Baihe Co. has refrained from providing detailed responses regarding the allegations, citing the ongoing second trial as a reason for their limited commentary [6]. - The situation remains unresolved, with both parties maintaining their positions, and market observers are closely monitoring the developments for clarity on the matter [6].